Home › Cardiovascular Disease › NCT05216042

GENESIS: Genotype Guided - Natriuretic Peptides - Cardiometabolic Health Study

Atrial Natriuretic Peptide and Regulation of Cardiometabolic Health: A Genotype-Guided Human Physiological Study

Who can join

Ages 18 and older · All sexes · Healthy volunteers welcome

Inclusion Criteria:

* Adults: Age more than or equal to 18; an equal number of Males and Females
* Consent to the collection of genetic material
* Willing to adhere to the study protocol

Exclusion Criteria:

* Age \<18, at screening.
* BMI \>45 kg/m2.
* Blood pressure more than 140/90 mmHg.
* Participants who are taking more than 2 hypertension medications.
* History of diabetes or fasting plasma glucose \>126 mg/dl or HbA1C\>=6.5% or prior treatment with antidiabetic medication.
* Have any past or present history of cardiovascular diseases (stroke, seizure, myocardial infarction, heart failure, transient ischemic attack, angina, or cardiac arrhythmia)
* Women who are pregnant or breastfeeding or who can become pregnant and not practicing an acceptable method of birth control during the study (including abstinence);
* Estimated GFR \< 60 ml/min/1.73 m2; albumin creatinine ratio ≥30 mg/g
* Hepatic Transaminase (AST and ALT) levels \>3x the upper limit of normal
* Anemia (men, Hct \< 38%; women, Hct \<36%)
* Inability to exercise on a treadmill

About the study

Natriuretic Peptides (NP) are hormones produced by the heart, and they have a wide range of favorable metabolic benefits. Lower levels of these hormones are associated with an increased likelihood of the development of diabetes and poor cardiometabolic health. Obese and Black individuals have \~30% lower levels of NP and are at a greater risk of developing cardiovascular (CV) events as compared to lean and White counterparts. Some people have common genetic variations that cause them to have \~20% lower NP levels. Similar to other low NP populations, these individuals with low NP genotype (i.e., carrying a common genetic variation called rs5068) are at a greater risk of developing cardiometabolic diseases. By understanding the NP response following the exercise challenge and the glucose challenge in individuals with genetically lower NP levels will help us understand how to improve cardiometabolic health in them.

What is being tested

• Study diet (dietary supplement)
• Exercise capacity VO2 max determination (other)
• Exercise Challenge (other)
• Glucose Challenge (other)

Sponsor: University of Alabama at Birmingham · Participants: 200 · Started: Apr 1, 2022

Contact the study team

• Nehal Vekariya, MS · Phone: 205-934-7173

Official record on ClinicalTrials.gov — NCT05216042

Locations in the U.S.

Conditions

• Cardiovascular Disease
• Obesity

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.